[Effects of concurrent therapy for patients with osteoporosis].
In the WHO technical report, vitamin D metabolites have been suggested to have a role as an adjunctive therapy when given with an antiresorptive agent. Beneficial effects on BMD have been reported following the addition of calcitriol to alendronate, etidronate, and HRT, but no data on fracture rates are available. Here we summarize our clinical study on the concurrent therapy and review reports on the concurrent treatments.
Kobayashi
Seneki
S
Department of Orthopaedic Surgery, Shinshu University School of Medicine, USA.
Shiraki
Masataka
M
Takaoka
Kunio
K
D000368:Aged; D015519:Bone Density; D002762:Cholecalciferol / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D015914:Estrogen Replacement Therapy; D012968:Etidronic Acid / Q000008:administration & dosage*; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D010024:Osteoporosis / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control*; D024482:Vitamin K 2 / Q000008:administration & dosage*
D004164:Diphosphonates; D024482:Vitamin K 2; D002762:Cholecalciferol; D012968:Etidronic Acid